ALIMERA SCIENCES, INC. Forms 3, 4 and 5: Stock Options
Statements of beneficial ownership filed with the SEC by officers, directors and 10% owners: 10 rows in 2021. Transaction codes are the SEC's. Shares and prices are split-adjusted; the as-filed figure is underneath.
- 2021-11-30: Reporting owner Parsons Erin; Form 4; Security Stock Option (Right to Buy); Transaction A Grant, award or other acquisition pursuant to Rule 16b-3(d).
- 2021-11-02: Reporting owner Kong Garheng; Form 4; Security Stock Option (Right to Buy); Transaction A Grant, award or other acquisition pursuant to Rule 16b-3(d).
- 2021-11-02: Reporting owner Halak Brian K; Form 4; Security Stock Option (Right to Buy); Transaction A Grant, award or other acquisition pursuant to Rule 16b-3(d).
- 2021-11-02: Reporting owner Pizzo Peter J. III; Form 4; Security Stock Option (Right to Buy); Transaction A Grant, award or other acquisition pursuant to Rule 16b-3(d).
| Transaction date | Reporting owner | Form | Security | Transaction | Shares | Price | Price that day | Filing |
|---|---|---|---|---|---|---|---|---|
| 2021-11-30 | Parsons Erin Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +3,255 3,255 owned after | $5.23 exercise price | 2021-12-02 | |
| 2021-11-02 | Kong Garheng Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +6,000 6,000 owned after | $4.05 exercise price | 2021-11-04 | |
| 2021-11-02 | Halak Brian K Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +6,000 6,000 owned after | $4.05 exercise price | 2021-11-04 | |
| 2021-11-02 | Pizzo Peter J. III Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +6,000 6,000 owned after | $4.05 exercise price | 2021-11-04 | |
| 2021-11-02 | Snisarenko John Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +6,000 6,000 owned after | $4.05 exercise price | 2021-11-04 | |
| 2021-11-02 | Largent James R Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +6,000 6,000 owned after | $4.05 exercise price | 2021-11-04 | |
| 2021-01-07 | Jones John Philip Officer (Chief Financial Officer) | 4 | Employee Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +16,875 16,875 owned after | $5.01 exercise price | 2021-01-11 | |
| 2021-01-07 | Ashman Philip Officer (Chief Operating Officer & SVP) | 4 | Employee Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +30,000 30,000 owned after | $5.01 exercise price | 2021-01-11 | |
| 2021-01-07 | Kaba Samer Officer (Chief Medical Officer) | 4 | Employee Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +18,750 18,750 owned after | $5.01 exercise price | 2021-01-11 | |
| 2021-01-07 | Holland David Officer (Chief Marketing Officer & SVP) | 4 | Employee Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +16,875 16,875 owned after | $5.01 exercise price | 2021-01-11 |